Three key pieces of data from expression profiling consistently support a greater presence of tumor associated B cells in SurVaxM LT survivors: (i) significant upregulation of C4BPA, an activating ligand of CD40 on antigen presenting cells; (ii) significant enrichment of humoral and complement related pathways by GSEA; and (iii) significantly higher immune deconvolution scores for memory and class-switched memory B cells. The gene discussed is C4BPA; the disease is neoplasm.